



HealthLinX Limited

Australian OvPlex™ distributor acquired by Healthscope

26 August 2009: The Directors of HealthLinX (ASX:HTX) have noted with interest today's announcement by national listed healthcare provider, Healthscope (ASX:HSP), that it has acquired ARL Pathology. ARL is the Australian distributor of HealthLinX's OvPlex™ early stage ovarian cancer diagnostic. The Directors believe that the impact of this acquisition should be positive for the company, as it will result in a greatly enlarged distribution network for OvPlex™. The Directors will provide further information as it comes to hand.

Enquiries

Nick Gatsios, HealthLinX Limited	+61 3 9208 4200
Rudi Michelson, Monsoon Communications rudim@monsoon.com.au	+61 3 9620 3333

About HealthLinX Limited (ASX:HTX)

HealthLinX uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality:

- Ovarian cancer diagnostic (OvPlex) targeting US\$270m pa market
- Prostate cancer targeting US\$350m pa market

A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.

Commercial sales of the OvPlex test have begun in Australia and are soon to commence in the UK. HealthLinX is developing new and increasingly accurate next generation diagnostics and will seek license partners to roll out worldwide sales.

www.healthlinx.com.au